TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03861403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV infusion
Study: NCT03601650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful eating
Description: Attending to the sensory properties of food as it is eaten

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eating without distractions
Description: Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
Study: NCT02351310

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
Study: NCT03208881

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary Supplement: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study: NCT03751956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
Study: NCT05912439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SidekickHealth
Description: Usage of mobile application called SidekickHealth.
Study: NCT03067142

Intervention type: OTHER
Intervention: Observational
Description: Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
Study: NCT01722344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS plus
Description: Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
Study: NCT01212471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic Solution A
Description: sterile ophthalmic solution
Study: NCT03067142

Intervention type: OTHER
Intervention: Observational
Description: Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.

Intervention type: OTHER
Intervention: Observational
Description: Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
Study: NCT04231513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.
Study: NCT05912439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SidekickHealth
Description: Usage of mobile application called SidekickHealth.
Study: NCT00769093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: 2 mg/kg
Study: NCT01212471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic Solution B
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: sterile ophthalmic solution
Study: NCT00976638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chromogenic surveillance
Description: All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
Study: NCT00295295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency, low magnitude vibration
Description: High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standing
Description: Standing 10 min/day
Study: NCT04231513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814-matched placebo
Description: E2814-matched placebo, intravenous infusion.
Study: NCT04428333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Cisplatin/carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum based chemotherapy
Description: Cisplatin/carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5FU)
Description: 5-fluorouracil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil (5FU)
Description: 5-fluorouracil
Study: NCT01936623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Brief Intervention
Description: No additional information needed.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized Brief Intervention
Description: No additional information needed.
Study: NCT03559166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo
Study: NCT03452085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: artificial saliva spray (AS)
Description: cross over design
Study: NCT03559166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: Randomized to active product or placebo
Study: NCT01271751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Study: NCT00976638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Molecular surveillance
Description: All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
Study: NCT01791660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq Coolsculpting System
Description: Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
Study: NCT03191162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
Study: NCT06090630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo DWI-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MR spectroscopic imaging
Study: NCT01106157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globin (ATG)
Description: Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated GCSF
Description: 6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
Study: NCT03230318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: derazantinib
Description: Derazantinib was administered orally at 300 mg once daily
Study: NCT02705482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0562
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0562
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
Study: NCT02075424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salivary sampling by a biomnis swab
Description: Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville.
Study: NCT00885183

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture therapy
Description: 12 acupuncture treatment sessions for a period of 16 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Description: 12 acupuncture treatment sessions for a period of 16 weeks
Study: NCT01234181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoxia-stressed BMSCs transplantation to cure MI
Description: Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hypoxia-stressed BMSCs transplantation to cure MI
Description: Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
Study: NCT02137642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
Study: NCT02659475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHEN/TPM ER (Qsymia®)
Description: PHEN/TPM ER (Qsymia®)
Study: NCT02137642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind placebo will be delivered once by injection during study procedure.
Study: NCT00572416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Sleep Promotion Plan
Description: Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Eating Control
Description: Equal time and attention and information about healthy eating
Study: NCT02141672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin High Dose
Study: NCT02048267

Intervention type: PROCEDURE
Intervention: Frey's procedure/Pylorus preserving pancreatoduodenectomy
Description: Duodenum preserving head resection
Study: NCT02141672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin Low Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02512289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS (ELDITH) and RAT (REAplan)
Description: Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (ELDITH) and RAT (REAplan)
Description: Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
Study: NCT02688192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participate in fitness program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participate in fitness program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Engage in private social support messaging and Use the mobile app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Engage in private social support messaging and Use the mobile app

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Wear an electronic accelerometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Wear an electronic accelerometer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02688192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03805854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz tACS of the bilateral somatosensory cortex
Description: 10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz tACS of the prefrontal cortex
Description: 10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 80 Hz tACS of the bilateral somatosensory cortex
Description: 80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 80 Hz tACS of the prefrontal cortex
Description: 80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation of the bilateral somatosensory cortex
Description: 10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
Study: NCT03037307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Five strips of test adhesive cream for upper denture, as per application instructions.
Study: NCT03805854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation of the prefrontal cortex
Description: 10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
Study: NCT03058198

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-ABT806 PET
Description: Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
Study: NCT02994485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
Study: NCT06374680

Intervention type: PROCEDURE
Intervention: laminectomy at C3 level
Description: laminectomy at C3 level

Intervention type: PROCEDURE
Intervention: laminectomy at C3 level
Description: laminectomy at C3 level
Study: NCT02941770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavior change
Description: Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavior change
Description: Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.